Nita Ahuja

Last updated

Nita Ahuja is a surgeon and the Chair of the Department of Surgery at Yale School of Medicine and Surgeon-in-Chief of Surgery at Yale New Haven Hospital. [1] [2] She is the first woman ever to serve as Chair of Surgery in Yale in its >200 year history. Before taking this position she was the first woman ever to be the Chief of Surgical Oncology at Johns Hopkins Hospital, Baltimore, USA. [3] Ahuja researches in the field of epigenetics and is a passionate advocate of clinician scientist. [4] She also served as the director of Sarcoma and peritoneal surface malignancy program. She is a surgeon-scientist and her research has been cited more than 11,000 times in scientific literature. [5]

Contents

Early life and education

Born in India, she migrated to the United States with her parents when she was 8 years old. [6] Her journey into the world of science started as a laboratory technician in Dept. of Immunology, National Institutes of Health (NIH), Bethesda. She was awarded with "Outstanding College Students of America" and "Alpha-omega-alpha original research award" for her outstanding research work. She joined the faculty of Johns Hopkins in 2003 after studying medicine at Duke University and surgery at Johns Hopkins. [3]

Career

Ahuja runs a research laboratory focused on understanding the epigenetic dysregulation in gastrointestinal cancers such as colorectal cancers and pancreas cancers and translating the information to develop biomarkers and epigenetic therapeutics. [7] She has led over twenty national and international clinical trials on testing new therapies in gastrointestinal and breast cancers based on concepts identified in her laboratory. [8] Her work initially as a postdoctoral research fellow twenty years ago identified the concept of CpG island methylator phenotype (CIMP) or CpG island hypermethylation in colorectal cancer. [9] This concept of CIMP now is known to have implications for prognosis as well as response to therapy. [10] CIMP has now been shown to exist in multiple other tumor types such as glioblastomas, leukemia, duodenal cancers etc. [11] [12]

Her laboratory has also identified biomarkers for early detection of colorectal and pancreas cancer using non-invasive body fluids such as serum or plasma. [13] These biomarkers have been licensed and are currently being developed into a commercial assay. [14]

Ahuja also led the epigenetic therapy trials in solid tumors as part of the Stand Up To Cancer consortium since 2008 and since then her laboratory has generated preclinical data for the next generation of clinical epigenetic trials conducted nationally and internationally. [15] [16] She has won several awards over the years including the Abell Foundation Award: Johns Hopkins Alliance for Science and Technology Development in 2014. [17]

Writing

She is co-author of a 2016 report for the Society of University Surgeons on barriers facing surgeon-scientists in basic science. [18] She also co-authored Along with Soft Tissue Sarcomas, An Issue of Surgical Clinics (Volume 88-3) (The Clinics: Surgery (Volume 88-3)). [19]

As well as Johns Hopkins guides for patients, including:

Related Research Articles

<span class="mw-page-title-main">Pancreatic cancer</span> Type of endocrine gland cancer

Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. A number of types of pancreatic cancer are known.

<span class="mw-page-title-main">Pancreaticoduodenectomy</span> Major surgical procedure involving the pancreas, duodenum, and other organs

A pancreaticoduodenectomy, also known as a Whipple procedure, is a major surgical operation most often performed to remove cancerous tumours from the head of the pancreas. It is also used for the treatment of pancreatic or duodenal trauma, or chronic pancreatitis. Due to the shared blood supply of organs in the proximal gastrointestinal system, surgical removal of the head of the pancreas also necessitates removal of the duodenum, proximal jejunum, gallbladder, and, occasionally, part of the stomach.

<span class="mw-page-title-main">Small intestine cancer</span> Medical condition

Small intestine cancer starts when cells in the small intestine start to grow out of control. The small intestine is the largest part of the gastrointestinal tract, which processes food for energy and rids the body of solid waste. The small intestine is not as common as other cancers of the GI tract such as colon, rectal, stomach, and esophageal cancers in the United States. They account for fewer than 1 in 10 cancers in the GI tract, and fewer than 1 in 100 cancers overall.

<span class="mw-page-title-main">Pancreatoblastoma</span> Medical condition

Pancreatoblastoma is a rare type of pancreatic cancer. It occurs mainly in childhood and has a relatively good prognosis.

<span class="mw-page-title-main">KRAS</span> Protein-coding gene in humans

KRAS is a gene that provides instructions for making a protein called K-Ras, a part of the RAS/MAPK pathway. The protein relays signals from outside the cell to the cell's nucleus. These signals instruct the cell to grow and divide (proliferate) or to mature and take on specialized functions (differentiate). It is called KRAS because it was first identified as a viral oncogene in the KirstenRAt Sarcoma virus. The oncogene identified was derived from a cellular genome, so KRAS, when found in a cellular genome, is called a proto-oncogene.

<span class="mw-page-title-main">Steven Libutti</span> American surgeon and scientist

Steven Kenneth Libutti, M.D., F.A.C.S. is an American surgeon and scientist. In January 2017, he became the third permanent Director of the Rutgers Cancer Institute of New Jersey, Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences and the Senior Vice President for Oncology Services for RWJBarnabas Health, the largest health system in New Jersey. He is a tenured Professor of Surgery at the Rutgers Robert Wood Johnson Medical School. Libutti's work on the study of tumor angiogenesis and the tumor microenvironment has led to novel approaches for the treatment of cancer. He is also one of the pioneers of regional and targeted cancer therapy.

Jonathan J. Lewis is an American surgeon, biomedical researcher and entrepreneur. He was trained in surgery in South Africa, Britain, and the United States, and is a fellow of both the Royal College of Surgeons and the American College of Surgeons. Dr. Lewis was awarded an MB.B.Ch. from University of the Witwatersrand School of Medicine, and his Ph.D. in Molecular Biology from Witwatersrand and Yale School of Medicine. He completed his Surgical Residency at Charlotte Maxeke Johannesburg Academic Hospital and at Yale-New Haven Hospital. Lewis was a Professor of Surgery and Medicine Memorial Sloan-Kettering Cancer Center, before working in the biotechnology and healthcare industries, serving in several CEO and Chairman roles. He is currently chairman and co-founder of the Molecular Ninja Group and chairman and co-founder of Dugri Inc.

<span class="mw-page-title-main">Cancer epigenetics</span> Field of study in cancer research

Cancer epigenetics is the study of epigenetic modifications to the DNA of cancer cells that do not involve a change in the nucleotide sequence, but instead involve a change in the way the genetic code is expressed. Epigenetic mechanisms are necessary to maintain normal sequences of tissue specific gene expression and are crucial for normal development. They may be just as important, if not even more important, than genetic mutations in a cell's transformation to cancer. The disturbance of epigenetic processes in cancers, can lead to a loss of expression of genes that occurs about 10 times more frequently by transcription silencing than by mutations. As Vogelstein et al. points out, in a colorectal cancer there are usually about 3 to 6 driver mutations and 33 to 66 hitchhiker or passenger mutations. However, in colon tumors compared to adjacent normal-appearing colonic mucosa, there are about 600 to 800 heavily methylated CpG islands in the promoters of genes in the tumors while these CpG islands are not methylated in the adjacent mucosa. Manipulation of epigenetic alterations holds great promise for cancer prevention, detection, and therapy. In different types of cancer, a variety of epigenetic mechanisms can be perturbed, such as the silencing of tumor suppressor genes and activation of oncogenes by altered CpG island methylation patterns, histone modifications, and dysregulation of DNA binding proteins. There are several medications which have epigenetic impact, that are now used in a number of these diseases.

Carolyn Kaelin was an American cancer surgeon. She worked at the Dana–Farber Cancer Institute and founded the Comprehensive Breast Health Center at Brigham and Women’s Hospital in 1995.

Stephen Bruce Baylin is the deputy director and associate director for research at the Sidney Kimmel Comprehensive Cancer Center and Virginia and D.K. Ludwig Professor for Cancer Research and medicine and chief of cancer biology of the Johns Hopkins University School of Medicine. His research focus is epigenetics in the development of cancer, and he was one of the first researchers in this field in the 1980s.

<span class="mw-page-title-main">Elizabeth Jaffee</span> American oncologist

Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.

CpG island hypermethylation is a phenomenon that is important for the regulation of gene expression in cancer cells, as an epigenetic control aberration responsible for gene inactivation. Hypermethylation of CpG islands has been described in almost every type of tumor.

<span class="mw-page-title-main">Julie Ann Sosa</span> American surgeon

Julie Ann Sosa, MD, MA, FACS, is professor and chair of the Department of Surgery at the University of California, San Francisco (UCSF) and holds the Leon Goldman, MD, Distinguished Professorship in Surgery. She currently serves as the Treasurer of the American Thyroid Association and Editor-in-Chief of the World Journal of Surgery.

<span class="mw-page-title-main">Jeffrey Drebin</span> American physician

Jeffrey Drebin is a surgeon and scientist. He serves as the Department of Surgery Chair at Memorial Sloan Kettering.

Fabrizio Michelassi, M.D., F.A.C.S. is the Lewis Atterbury Stimson Professor, and Chairman of the Department of Surgery at Weill Cornell Medicine and Surgeon-in-Chief at NewYork-Presbyterian/Weill Cornell Medical Center.

Julie Ann Freischlag is an American vascular surgeon and current CEO of Atrium Health Wake Forest Baptist. She was the first female surgeon-in-chief of The Johns Hopkins Hospital and the first female chief of vascular surgery at the University of California, Los Angeles. In 2017, Freischlag was appointed Interim Dean of Wake Forest School of Medicine and CEO of the Wake Forest Baptist Medical Center. During the COVID-19 pandemic in North America, Freischlag was named chief academic officer of Atrium Health, Inc., and appointed the President-Elect of the American College of Surgeons.

John Lemuel Cameron (1936-) is an American surgeon. He is the Alfred Blalock Distinguished Service Professor of Surgery at the Johns Hopkins School of Medicine.

Nilofer Saba Azad is an American oncologist and physician-scientist specialized in gastrointestinal, colorectal, cholangiocarcinoma, and pancreaticobiliary cancers. She is a professor at the Johns Hopkins School of Medicine and oversees clinical trials at the Sidney Kimmel Comprehensive Cancer Center.

<span class="mw-page-title-main">Monica Bertagnolli</span> American surgical oncologist (born 1959)

Monica Bertagnolli is an American surgical oncologist and the 16th director of the National Cancer Institute. Previously, she worked at Brigham and Women's Hospital and Dana–Farber Cancer Institute and was the Richard E. Wilson Professor of Surgery at Harvard Medical School. She has advocated for inclusion of rural communities in clinical studies and served as Chair of the Alliance for Clinical Trials in Oncology until her appointment to lead NCI. Bertagnolli specializes in the treatment of tumors from gastrointestinal diseases and soft tissue sarcomas. She is the former President of the American Society of Clinical Oncology and was elected Fellow of the National Academy of Medicine in 2021. In 2023, President Biden nominated Bertagnolli to serve as the director of the National Institutes of Health. If confirmed, she would be the second woman director of the NIH.

Timothy Michael Pawlik is an American surgical oncologist. He is Chair of the Department of Surgery and the Urban Meyer III and Shelley Meyer Chair for Cancer Research at The Ohio State University and Surgeon-in-Chief at The Ohio State University Wexner Medical Center.

References

  1. ↑ "Nita Ahuja Named Chair of Surgery". 16 November 2017. Retrieved 5 September 2019.
  2. ↑ "Nita Ahuja > Doctor at Yale Medicine". Yale Medicine. Retrieved 2020-07-22.
  3. 1 2 "Nita Ahuja M.D." HopkinsMedicine.org. Johns Hopkins School of Medicine. Retrieved 23 April 2017.
  4. ↑ "Nita Ahuja, MD, MBA, FACS". medicine.yale.edu. Retrieved 2022-04-14.
  5. ↑ "Nita Ahuja, MD, MBA, FACS". Yale School of Medicine. Retrieved 2020-07-22.
  6. ↑ "A New Direction for Surgery". Yale Medicine. Retrieved 2022-05-16.
  7. ↑ Ahuja, Nita; Easwaran, Hariharan; Iacobuzio-Donahue, Christine. "(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer".{{cite journal}}: Cite journal requires |journal= (help)
  8. ↑ "Nita Ahuja, MD, MBA, FACS". medicine.yale.edu. Retrieved 2022-04-18.
  9. ↑ Toyota, M.; Ahuja, N.; Ohe-Toyota, M.; Herman, J.G.; Baylin, S.B.; Issa, J.P. (July 1999). "CpG island methylator phenotype in colorectal cancer". Proc. Natl. Acad. Sci. U.S.A. 96 (15): 8681–6. Bibcode:1999PNAS...96.8681T. doi: 10.1073/pnas.96.15.8681 . PMC   17576 . PMID   10411935.
  10. ↑ Ahuja, Nita. "Epigenetic markers involved in colorectal cancer recurrence and metastases".{{cite journal}}: Cite journal requires |journal= (help)
  11. ↑ "Nita Ahuja, MD, MBA - Google Scholar". scholar.google.com. Retrieved 2020-07-22.
  12. ↑ "Dr. Nita Ahuja, MD – New Haven, CT | General Surgery on Doximity". Doximity. Retrieved 2020-07-22.
  13. ↑ Yi, J.M.; Guzzetta, A.A.; Bailey, V.J.; Downing, S.R.; Van Neste, L.; Chiappinelli, K.B.; Keeley, B.P.; Stark, A.; Herrera, A.; Wolfgang, C.; Pappou, E.P.; Iacobuzio-Donahue, C.A.; Goggins, M.G.; Herman, J.G.; Wang, T.H.; Baylin, S.B.; Ahuja, N. (1 December 2013). "Novel methylation biomarker panel for the early detection of pancreatic cancer". Clinical Cancer Research. 19 (23): 6544–55. doi:10.1158/1078-0432.CCR-12-3224. PMC   4310572 . PMID   24088737.
  14. ↑ "Hey Siri Should I Get a Medical Degree - The ASCO Post". www.ascopost.com. Retrieved 2020-07-22.
  15. ↑ Azad, N.S.; El-Khoueiry, A.; Yin, J.; Oberg, A.L.; Flynn, P.; Adkins, D.; Sharma, A.; Weisenberger, D.J.; Brown, T.; Medvari, P.; Jones, P.A.; Easwaran, H.; Kamel, I.; Bahary, N.; Kim, G.; Picus, J.; Pitot, H.C.; Erlichman, C.; Donehower, R.; Shen, H.; Laird, P.W.; Piekarz, R.; Baylin, S.; Ahuja, N. (2017). "Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study". Oncotarget. 8 (21): 35326–35338. doi:10.18632/oncotarget.15108. PMC   5471058 . PMID   28186961.
  16. ↑ Connolly, R.M.; Li, H.; Jankowitz, R.C.; Zhang, Z.; Rudek, M.A.; Jeter, S.C.; Slater, S.A.; Powers, P.; Wolff, A.C.; Fetting, J.H.; Brufsky, A.; Piekarz, R.; Ahuja, N.; Laird, P.W.; Shen, H.; Weisenberger, D.J.; Cope, L.; Herman, J.G.; Somlo, G.; Garcia, A.A.; Jones, P.A.; Baylin, S.B.; Davidson, N.E.; Zahnow, C.A.; Stearns, V. (2017). "Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study". Clin Cancer Res. 23 (11): 2691–2701. doi:10.1158/1078-0432.CCR-16-1729. PMC   5457329 . PMID   27979916.
  17. ↑ "Nita Ahuja, MD, MBA, FACS". medicine.yale.edu. Retrieved 2022-05-16.
  18. ↑ Keswani, S.G.; Moles, C.M.; Morowitz, M.; Zeh, H.; Kuo, J.S.; Levine, M.H.; Cheng, L.S.; Hackam, D.J.; Ahuja, N.; Goldstein, A.M. (2016). "The Future of Basic Science in Academic Surgery: Identifying Barriers to Success for Surgeon-scientists". Annals of Surgery. Basic Science Committee of the Society of University Surgeons. 265 (6): 1053–1059. doi:10.1097/SLA.0000000000002009. PMC   5450912 . PMID   27643928.
  19. ↑ Hueman, Matthew T.; Ahuja, Nita (2008). Soft Tissue Sarcomas. ISBN   978-1416058052.
  20. ↑ Ahuja, Nita; Coleman, JoAnn (2010). Johns Hopkins Patients' Guide to Pancreatic Cancer. Jones & Bartlett Learning. ISBN   9781449632762.
  21. ↑ Ahuja, Nita; Coleman, Joann (22 December 2010). Johns Hopkins Patients' Guide to Pancreatic Cancer. ISBN   978-0763774585.
  22. ↑ Johns Hopkins Patient Guide to Colon and Rectal Cancer. Jones & Bartlett Learning. 7 March 2013. Retrieved 2020-07-22– via www.amazon.com.
  23. ↑ Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer: Expert Consult. Saunders. 15 July 2010. Retrieved 2020-07-22– via www.amazon.com.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.